The Medical Briefing  Nephrology

Atrasentan in IgA nephropathy, predictive antihypertensive prescribing, finerenone in type 1 diabetes, metformin and polycystic kidney disease

Retrospective no. 6/12

The essentials in four articles

■ Glomerular disease
404 patients, 2.5 years: atrasentan +2.4 mL/min/1.73 m² of GFR at 136 weeks, annual slope slowed by 1.4 mL/min/1.73 m²/year, including on SGLT2 inhibitors. Overall reassuring safety profile.

■ Clinical nephrology
Meta-analysis of 484 trials (104,176 patients): standard-dose monotherapy −8.7 mmHg systolic, doubling the dose about −1.5 mmHg more, dual therapy −14.9 mmHg. The BPModel tool estimates the expected drop by drug and dose.

■ CKD and dialysis
242 adults with type 1 diabetes and albuminuric CKD: UACR −34% with finerenone vs −12% with placebo at 6 months (additional relative reduction of 25%), hyperkalemia 10% vs 3%.

■ CKD and dialysis
Short post: metformin activates AMPK and inhibits the mTOR pathway, which could slow cyst growth in polycystic kidney disease; the IMPEDE-PKD trial has reached 30 investigator sites.